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Background: This study examined medical resource utilisation patterns in the United Kingdom (UK) prior to and
following Alzheimer’s disease (AD) diagnosis.
Methods: A patient cohort aged 65 years and older with newly diagnosed AD between January 2008 and
December 2010 was identified through the UK’s Clinical Practice Research Datalink (CPRD). Patients with a
continuous record in the CPRD (formerly the General Practice Research Database [GPRD]) for both the 3 years prior
to, and the 1 year following, AD diagnosis were eligible for inclusion. A control cohort was identified by matching
general older adult (GOA) patients to patients with AD based on year of birth, gender, region, and Charlson
Comorbidity Index at a ratio of 2:1. Medical resource utilisation was calculated in 6-month intervals over the 4-year
study period. Comparisons between AD and GOA control cohorts were conducted using conditional logistic
regression for patient characteristics and a generalised linear model for resource utilisation.
Results: Data for the AD cohort (N = 3,896) and matched GOA control cohort (N = 7,792) were extracted from the
CPRD. The groups were 65% female and the AD cohort had a mean age of 79.9 years (standard deviation 6.5 years)
at the date of diagnosis. Over the entire study period, the AD cohort had a significantly higher mean primary care
consultation rate than the GOA cohort (p < .0001). While the GOA cohort primary care consultation rate gradually
increased over the 4-year period (ranging from 5 to 7 consultations per 6-month period), increases were more
pronounced in the AD cohort (ranging from 6 to 11 consultations per 6-month period, peaking during the 6-month
periods immediately prior to and post diagnosis). The AD cohort also had a higher overall specialty referral rate than
the GOA cohort over the 4-year period (37% vs. 25%, respectively; p < .0001); the largest difference was during the
6 months immediately prior to AD diagnosis (17% vs. 5%, respectively; p < .0001).
Conclusions: In the UK, AD diagnosis is associated with significant increases in primary and secondary care resource
utilisation, continuing beyond diagnosis. This evidence may be important to health care commissioners to facilitate
effective mobilisation of appropriate AD-related health care resources.
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Across Europe, the 6.3 million patients living with demen-
tia impose a high financial burden. With a total annual
health care cost of €16.95 billion (€2673 per patient) and a
total non-medical cost of €88.2 billion (€13,911 per pa-
tient), the impact of dementia on the financial health of
Europe should not be under-estimated [1]. Alzheimer’s
disease (AD) is the most common form of dementia,
and accounts for over 60% of all cases [2]. In the United
Kingdom (UK) about 400,000 patients have AD [2], and
the incidence rates double as age increases by 5 years
(after 75 years of age) [3]. While 1 person in 88 of the
entire UK population has a form of dementia, that ratio
jumps to 1 person in 14 over age 65, and to 1 person in
6 over age 80 [2].
Clinical diagnosis of probable AD, like many neuro-
cognitive disorders, relies on examination of the patient’s
physical and mental state in consultation with a close
friend or relative of the patient and requires identifica-
tion of a cognitive abnormality alongside inability of the
patient to carry out daily living activities [4,5]. The sub-
jective process of diagnosing dementia or AD often results
in a lengthy gap between symptom onset and diagnosis
[6]. In a recent survey of UK patients with dementia, 68%
had experienced a 1-year or longer delay in diagnosis,
while 8% reported a delay of 5 years or longer [7]. Al-
though recent advances in brain imaging along with the
identification of distinctive and reliable biomarkers [4] in-
dicate potential for the diagnostic process to be more ob-
jective, there are issues of resources and reliability to be
considered before these become part of routine care.
There are currently no treatments available that can
alter the progressive course of dementia. However, there
are treatments that can assist in symptom management
[2]. For patients with mild to moderate AD, three acetyl-
cholinesterase (AChE) inhibitors are available (donepezil,
galantamine, and rivastigmine). Memantine is available
for patients with moderate to severe AD [8] and antide-
pressants, antipsychotics, and anxiolytics have been used
to treat psychological symptoms [2].
The cost of dementia care varies greatly depending on
the stage of the disease; in some studies the cost of care
was more than doubled between mild and severe demen-
tia [9,10]. Patients with dementia also have higher rates of
hospitalisation with longer duration of stay [11]. In fact, at
any given time, one-quarter of all hospital beds in the UK
are occupied by patients with dementia [12].
The burden of dementia and AD on the primary care
sector is not well understood [13]. Studies in the United
States (US) [13], the Netherlands [14], and Germany [15]
found that the number of primary care/ambulatory care
consultations (or the cost of that care) increased prior to
diagnosis and remained high immediately following diag-
nosis. Other studies in Denmark [11], the US [16], andFrance [17] found varying or even no differences in pri-
mary care resource utilisation in comparisons among pa-
tients with AD with differing degrees of impairment, and
versus non-AD dementia or control cohorts without de-
mentia. Strikingly, there are currently no published studies
that investigate the pattern of resource utilisation before
AD diagnosis in the UK.
In this retrospective cohort study, the goal was to
characterize the longitudinal pattern of medical resource
utilisation of individuals with AD prior to, and after,
their diagnosis and to compare those patterns with the
resource utilisation of matched control individuals, a
general older adult patient population without AD.
Methods
Data source
This study used electronic medical record data from the
UK Clinical Practice Research Datalink (CPRD), which
has evolved from the General Practitioner Research Data-
base (GPRD). The GPRD was established in 1987, and
data are gathered in a non-interventional way from the re-
cords of general practitioners in the UK. The anonymised
patient information includes demographics, diagnoses, co-
morbidities, and prescribing information. A detailed de-
scription of CPRD is available elsewhere [18-20].
CPRD has an established linkage between GPRD and the
Hospital Episode Statistics (HES) which was also used in
this study. The HES [21] is a data warehouse containing
details of all admissions to National Health Services (NHS)
hospitals in England including acute hospitals, primary
care trusts, and mental health trusts. The HES contains
admitted patient care data from 1989 onwards, and pro-
cesses more than 125 million records each year.
Sample selection
This study used an incidence-based, matched case–con-
trol design. Two cohorts of patients 65 years and older
were identified: (1) those who received a first diagnosis
of AD (AD cohort), and (2) a general older adult cohort
of patients who did not have a diagnosis of AD or de-
mentia (GOA cohort).
We identified patients who had the first diagnosis of AD
between 01 January 2008 and 31 December 2010. We de-
fined the index date as the first diagnosis of AD for a given
patient. Patients 65 years or older old at the index date were
included in the AD cohort. Patients also needed to have
a case history for at least 3 years before, and 1 year after,
the index date. We excluded those who had ever re-
ceived a diagnosis of early-onset AD, or had a non-AD
dementia diagnosis (including vascular dementia, dementia
with Lewy bodies, and frontotemporal dementia) during
the post-index period.
For each patient in the AD cohort, 2 general older
adults without an AD or other dementia diagnosis were
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comorbidity severity as measured by Charlson Comorbid-
ity Index (CCI) [22]. Since the studied condition is AD, a
type of dementia, our calculation of CCI omitted dementia
and only included a total of 16 physical conditions that
represent common conditions like cancer, diabetes melli-
tus, and cardiovascular disease. The matched GOA indi-
viduals were also required to have a complete case history
for the corresponding 4-year study period. If more than 2
patients met the matching criteria, 2 matched individuals
were selected randomly.
Ethics approval for this study was given by the Inde-
pendent Scientific Advisory Committee (ISAC) at CPRD
in 2012 (protocol number: 12-071R).
Patient characteristics
The AD and GOA cohorts were evaluated for the follo-
wing characteristics: (1) demographics (age, sex, region);
(2) baseline rates of selected comorbidities (hypertension,
depression, psychosis); and (3) baseline CCI score.
Measures of medical resource utilisation
The overall consultation rate was calculated as the sum of
all recorded consultations excluding administrative con-
sultations. More than one consulting record per day was
counted as one consultation [23]. Consultations were
classified into the following mutually exclusive categories:
‘GP (general practice) consultation’ (including consulta-
tions coded as clinic, surgery, and emergency consult-
ation), ‘house call’, ‘telephone consultation’, ‘third-party
consultation’ (friend, family, or guardian contact on be-
half of patient), and ‘other’.
The overall specialist referral rate was calculated, as were
as referrals to psychiatrists/memory clinics, neurologists,
and geriatrics. In the UK, AD is often diagnosed by spe-
cialists in a memory clinic [2]. As these specialists usually
have a psychiatric background — 79% of UK investigators
in the GERAS study were psychiatrists who specialize in
the care of elderly patients [24] — clinic visits are typically
coded as a psychiatric referral. AD-related drug utilisation
rates (including AChE inhibitors, memantine, antidepres-
sants, antipsychotics, and anxiolytics/sedatives) were mea-
sured. Hospital admissions were estimated based on the
HES-eligible subpopulation. The length of hospitalisation
was calculated by subtracting the admission date from the
discharge date for days within the study period. This ex-
cluded day case, which has a length of stay of zero days.
Data/statistical analyses
Descriptive statistics were presented by study cohort and
compared using a conditional logistic regression for non-
matched variables. To understand the longitudinal pattern
of the resource utilisation, the 4-year study period was di-
vided into eight 6-month intervals: six pre-index intervals(for a total of 3 years prior) and 2 post-index intervals (for
a total of 1 year post). Resource utilisation was calculated
for each interval. The resource utilisation between the AD
and GOA cohorts was first compared using t-tests, chi-
square tests, and Wilcoxon rank-sum tests depending
on the data type and distribution. To account for the
matched-case control study design, as well as to adjust
for the difference in individual comorbidities, resource
utilisation data were assessed using a generalised linear
model that accounted for correlation among repeated
measures. The models adjusted for differences in patient
characteristics, such as comorbidities of hypertension
and depression. Psychosis was not included as a covari-
ate in the model because the prevalence of this baseline
diagnosis was very low in both study cohorts.
All analyses were conducted using commercially avai-
lable statistical software (SAS version 9.2; SAS Institute
Inc., Cary, North Carolina). P-values < .05 were considered
statistically significant.Results
Cohort characteristics
The AD cohort included 3,896 patients who were matched
1:2 with 7,792 GOA control patients (Figure 1). Of these,
1,785 patients (45.8%) in the AD cohort and 3,407 patients
(43.7%) in the GOA cohort comprised the HES subpopu-
lation. As a result of the case-control design, the mean age
(79.9 years), gender (65% female), CCI (mean 0.69 and
36.2% with CCI ≥ 1), and geography (73% from England)
were the same for both groups (Table 1). More patients in
the AD cohort than in the GOA cohort had reported de-
pression (16.5% vs. 9.2%; p < .0001) and psychosis (0.31%
vs. 0.04%; p = .0013); in contrast, fewer patients in the AD
cohort had hypertension compared with GOA patients
(9.3% vs. 10.5%; p = .0351) (Table 1). In the HES subpopu-
lation, AD and GOA cohorts were comparable in terms of
age, gender, and geographic region. However, HES-eligible
AD cohort patients were significantly less likely to have at
least one chronic physical condition (i.e., CCI ≥ 1) than
GOA patients (37.4% vs. 39.4%; p = .0332).Consultation rates
Over the 4-year study period, the mean overall number of
total primary care consultations was significantly higher in
the AD cohort compared with GOA patients (64.8 vs. 48.7
overall total consultations; p < .0001). Total consultations
in the GOA cohort gradually increased over this period.
In the initial 6-month period, the mean number of total
consultations in the AD cohort was significantly higher
than in the GOA cohort (6.1 vs. 5.2 total consultations;
p < .0001) (Figure 2). The AD cohort then showed a sharp
increase (to 10.5 total consultations) during the 6-month
period prior to diagnosis; the rate remained high post
CPRD acceptable patients
(N=11,522,152)
Patients aged >65 with a first AD diagnosis between 01 January 2008 and 31 December 2010
(N=8,224)
Exclusion of patients with early-onset AD or a non-AD diagnosis after index date
(N=8,114)
Patients with continuous enrollment 3 years prior to and 1 year post index date
(N=3,911)
Matched with GOA controls
(N=3,896)
Figure 1 Patient data identification from the CPRD. Clinical Practice Research Datalink (CPRD) records identified patients with Alzheimer’s
disease (AD) diagnosed between 01 January 2008 and 31 December 2010, and a matched general older adult (GOA) cohort. Excluding ineligible
patients produced a cohort of 8,114 patients; 3,911 had continuous CPRD records throughout the 4-year study period and 3,896 were matched
1:2 with 7,792 GOA controls by birth year, gender, region, and comorbidity.
Table 1 Cohort characteristics
Patients with AD N = 3,896 GOA Controls N = 7,792 P-value
Age, mean years (standard deviation) 79.9 (6.5) 79.9 (6.5)






Female,% of patients 65.2% 65.2%
Geographic Region, % of patients
England 73.2% 73.2%
Northern Ireland 3.5% 3.5%
Scotland 14.6% 14.6%
Wales 8.7% 8.7%
CCIa, mean (range) 0.69 (0, 6) 0.69 (0, 6)
CCI≥ 1, % of patients 36.2% 36.2%
Hypertension, % of patients 9.3% 10.5% .0351
Depression, % of patients 16.5% 9.2% <.0001
Psychosis, % of patients 0.31% 0.04% .0013
AD = Alzheimer’s disease; GOA = general older adult; CCI = Charlson Comorbidity Index.
aCCI was calculated excluding dementia component.
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cohort (p < .0001) (Figure 2).
GOA patients had a stable GP consultation rate over
the 4-year study period (approximately 4 consultations
per 6 months), whereas the AD cohort had a slightly
higher GP consultation rate that was relatively stable
throughout the 4-year period except for a peak (to 5.4
GP consultations) occurring in the 6 months immedi-
ately prior to diagnosis (Figure 2).
Similar trends were observed for third-party consulta-
tions. The overall mean number of third-party consulta-
tions was significantly higher in the AD cohort than for
GOA patients (17.0 vs. 9.7 overall third-party consulta-
tions; p < .0001). In the initial 6-month period, the mean
number of third-party consultations for the AD cohort
was significantly higher compared with the GOA cohort
(0.6 vs. 0.5 third-party consultations; p = .0016) (Figure 2).
Over the 4-year study period, third-party consultations
increased steadily for GOA patients, whereas the AD
cohort showed an increase (to 3.4 third-party consulta-
tions) in the 6-month period prior to diagnosis that fur-
ther increased for a peak (4.3 third-party consultations) in
the first post-diagnosis period (Figure 2).
Specialty referral rates
The proportion of patients with at least one secondary
care specialty referral over the 4-year period was also
significantly higher in the AD cohort compared with
GOA patients (36.8% vs. 24.8%; p < .0001). While the
overall specialty referral rates were significantly higher
in the AD cohort compared with GOA patients for
neurology (1.0% vs. 0.5%; p = .0022) and geriatrics (3.1%
vs. 1.1%; p < .0001) referrals, the majority of the increase
in the total specialty referral rate for patients with AD
can be attributed to the high number of psychiatry refer-
rals (Figure 3). During the first 6-month period, 0.67% of
patients in the AD cohort received a psychiatry specialty
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Figure 2 Mean numbers of consultations per person. For total consulta
time interval. The x-axis values represent 6-month intervals pre- and post-in
adult; GP = general practise.immediately preceding diagnosis. In comparison,
psychiatry referrals remained stable in the GOA cohort
throughout the study at about 0.1% per 6-month
period (p < .0001 vs. AD cohort in all 6-month periods)
(Figure 3).
Prescription rates
In the first post-diagnosis 6-month period, 37.5% of pa-
tients in the AD cohort were prescribed at least one
AChE inhibitor (Figure 4). Unsurprisingly, due to the
way the cohort was defined, only 0.67% of the GOA co-
hort had been prescribed an AChE inhibitor over the 4-
year study period. In contrast, 46.6% of patients in the
AD cohort had been prescribed at least one AChE in-
hibitor (p < .0001). The AD cohort was also significantly
more likely than the GOA cohort to have been pre-
scribed memantine (2.5% vs. 0.13%; p = .0024), antide-
pressants (41.4% vs. 23.2%; p < .0001), and antipsychotics
(23.7% vs. 14.5%; p < .0001). However, there was no sig-
nificant difference between AD and GOA cohorts in the
proportion of patients prescribed anxiolytics (26.6% vs.
19.8%; p = .2178).
Hospitalisation rates
In the HES subpopulation, patients in the AD cohort
were significantly less likely to be hospitalised than were
HES-eligible GOA patients during the first 6-month
study period (13.2% vs. 16.0%; p = .0062) (Figure 5). How-
ever, patients in the AD cohort were significantly more
likely to be hospitalised than GOA patients in the 6 months
immediately prior to diagnosis (23.6% vs. 18.9%; p < .0001).
The higher rate of hospitalisation for the AD cohort versus
the GOA cohort continued through the final 6-month
study period (23.3% vs. 18.4%; p < .0001) (Figure 5). The
duration of hospitalisation was also increased; in the
6 months preceding AD diagnosis the mean length of
hospital stay for patients with AD was more than twice
that of GOA patients (1.9 days vs. 0.79 days; p < .0001).AD:    total consultations
GOA: total consultations
AD:    GP consultations
GOA: GP consultations
AD:    third-party consultations
GOA: third-party consultations
  1           2
Post-index
te
tions, AD vs. GOA comparisons were significant (p < .0001) at every








































AD:    total secondary care referrals
GOA: total secondary care referrals
AD:    psychiatric/memory clinic referrals
GOA: psychiatric/memory clinic referrals
-6 -5          -4          -3         -2          -1           1           2
Pre-index Post-index
6-month intervals pre- and post-index date
Figure 3 Proportion of patients with at least one new specialty referral. For total secondary care specialty referrals, AD vs. GOA comparisons
were significant (p < .02) at every time interval except the second post-index interval. The x-axis values represent 6-month intervals pre- and post-index
(AD diagnosis) date. AD = Alzheimer’s disease; GOA = general older adult.
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higher in the AD cohort versus the GOA cohort for the
year following AD diagnosis (p < .0001).
Discussion
This population- and incidence-based, matched case-
control study found that the burden on primary care
resources is higher in patients with AD versus their
demographic- and comborbidity-comparable elderly
control counterparts. The higher rates of primary care
resource utilisation are evident in the AD cohort relative
to GOA control patients as much as 3 years prior to AD
diagnosis, with a sharp increase in the AD cohort immedi-
ately preceding the AD diagnosis that is maintained in the
one year following diagnosis. This is the first study to re-
port such a finding in the UK, and is consistent with re-
sults of other studies [13-15]. In Albert et al., the burden
was measured by health care expenditures [13], while
Ramakers et al. and Eisele et al. both used primary care
consultation rates as a measure of health care burden
[14,15]. There are, however, some striking differences be-
tween the various study populations. Two of the studies
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Figure 4 Proportion of patients with at least one prescription for an A
comparisons were significant (p < .0001) at every time interval. The x-axis v
date. AChE = acetylcholinesterase; AD = Alzheimer’s disease; GOA = generalAD, while one study [15] had an AD cohort that was ap-
proximately half the size of that used for the current
study.
The initial primary care consultation rate observed for
the GOA control cohort in the current study (approxi-
mately 11 consultations per year) was consistent with
general medical utilisation patterns as documented in a
recent UK Department of Health report [25]. Although
this study does not reveal why patients were seeking pri-
mary care consultations, it is reasonable to assume that
the increases in consultation rates and referrals for pa-
tients in the AD cohort reflect the diagnostic process. If
so, diagnosis will be accompanied by an increase in
health care utilisation regardless of when it occurs. An-
other possibility is that patients with undiagnosed AD
may be less able to maintain healthy habits, such as
regular medication regimens. Thus, the peak in primary
care utilisation may reflect general health deterioration
as the patients’ daily living skills are increasingly com-
promised. It is also possible that these visits may be due
to sequelae subsequent to the AD, such as gait imbal-
ances [13]. It is notable that third-party consultations
(by guardians/family/friends on behalf of the patient) asAD:    any AChE inhibitor
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ChE inhibitor. For total AChE inhibitor prescriptions, AD vs. GOA








































6-month intervals pre- and post-index date
Figure 5 Proportion of patients with at least one hospital admission. HES-eligible patients included n = 1,785 for the AD cohort and
n = 3,407 for the GOA cohort. For AD vs. GOA comparisons, *p≤ .01 and **p < .0001. The x-axis values represent 6-month intervals pre- and
post-index (AD diagnosis) date. AD = Alzheimer’s disease; GOA = general older adult; HES = Hospital Episode Statistics.
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both the diagnostic pathway and general medical decline
may actively contribute to the observed increase in pri-
mary care utilisation. Further analysis is needed to elu-
cidate the specific contribution of the AD diagnostic
pathway versus medical needs.
This study also found that the AD cohort was more likely
to have a diagnosis or reported symptoms of depression
and/or psychosis, although the prevalence of psychosis was
lower than expected in both cohorts. Recent estimates are
of about 1% or higher of older-age adults exhibiting psych-
otic symptoms [26,27]. The low rates of psychosis in our
study and the contrasting higher antipsychotic prescrip-
tions rates in the AD cohort versus GOA patients may be a
result of prescriptions originating in a secondary care set-
ting or prescribing to patients in the absence of a psychosis
diagnosis. Our study also found lower rates of hypertension
in the AD cohort than the control cohort, which is surpris-
ing since hypertension is a known risk factor for AD. In
contrast, a German study reported higher rates in the AD
cohort than controls [15]. Notably, though, the proportions
of patients with hypertension in the GOA and AD cohorts
in our study were numerically close — statistical signifi-
cance of the small difference between cohorts could be an
artifact of the sample size — and may warrant further study
to understand the reason(s) for the observed rates.
The initial secondary care specialty referral rates for
the AD and GOA cohorts (6.9% and 5.8% in the first 6-
month period, respectively; if extrapolated these would
each be about 12% to 14% per year) were comparable
with previously published referral rates for the GPRD
(13.9% per year) [28]. The referral rates for the AD co-
hort were higher than the GOA cohort throughout the
study, and sharply increased in the AD cohort in the 6-
month period immediately preceding diagnosis (to
17.0%); this was largely driven by an increase inpsychiatric/memory clinic referrals in this time period
before diagnosis.
While GP practitioners are the cornerstone of medical
care, they have varying familiarity with AD and high de-
mands on their time and attention that may limit their
capacity to manage AD care. For this reason, the NHS
has established memory clinics throughout the UK and
recommends that AD be diagnosed within these clinics or
by a psychiatric specialist, since any prescribed pharmaco-
logical therapy (e.g., AChE inhibitor) should be initiated
by a specialist. Per treatment guidelines, such clinics
should be the single point of referral for possible de-
mentia diagnosis [8]. However, this study found that
about 90% of patients with an AD diagnosis in their
medical record were not referred to a psychiatry/mem-
ory clinic specialist by their GP provider. It is likely that
some patients were referred by non-GP physicians, such
as during an unrelated hospital admission, although
some of these AD diagnoses were perhaps initiated dir-
ectly by the GP practitioner. As a result, there may be
variability around the exact criteria used for initial diagno-
sis and extent of disease progression at that time.
There is growing interest in the quick, efficient diag-
nosis and early intervention for AD, considering the high
resource utilisation prior to and post diagnosis (in the
current diagnostic pathway) may be related to both the
progressive nature of the disease and the often lengthy
diagnosis process. Albert et al. calculated that undiag-
nosed AD is responsible for $130 million to nearly $200
million in excess cost to the US each year [13]. While
the number of patients with AD is much smaller in the
UK than in the US, the increase in medical consultations
is likely to impose a significant financial burden on the
UK. There is keen interest in early treatment of neuro-
cognitive diseases, as treatments may be most effective
when structural changes to the brain are minimal [5];
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under development for the treatment of early-stage AD.
In addition, emergence of new clinical tools may provide
the means to increase the efficiency of diagnosis, including
reducing rates of false-positive and false-negative diagno-
ses that can contribute to the high cost and resource con-
sumption of primary care of dementia patients [29].
Reassuringly, nearly 50% of the AD cohort was prescribed
an AChE inhibitor within 1 year of diagnosis, adhering to
the 2012 NICE treatment guidelines recommending treat-
ment for patients with both mild and moderate to severe
AD [8]. While it is unclear at this time whether earlier
diagnosis of AD would subsequently decrease the burden
on the health care system, there is evidence that early AD
diagnosis decreases subsequent primary health care medical
costs [30]. Our study did not address the timing of AD
diagnosis as a factor in the health care resource burden on
primary care. However, given the current challenges in the
diagnostic pathway, combined with our evidence of the sig-
nificant burden this places on primary care, it is reasonable
to hypothesise that increasing the efficiency of diagnosis
could improve resource and cost management for GP
providers. This might be accomplished in several ways,
including shortening the duration and/or streamlining
the process from the time of onset of AD symptoms in
the GP setting to subsequent diagnostic confirmation
and mobilisation of appropriate care.
This study relied entirely on electronic medical records;
eligible patients were identified from over 11 million
patients in the CPRD. This population-based approach
should provide a cross-section of rural/urban location,
race, and socio-economic status, avoiding many biases in-
herent in studies focused on a specific region or clinic.
There were 11,688 patients in the study population, a far
larger sample size than is easily obtainable from in-person
interviews. Most importantly, the resource utilisation pat-
terns described herein occurred in the real-world context
of diverse UK communities. The longitudinal design was
an advantage, as it followed patients for the 3-year period
prior to AD diagnosis and 1-year post. This is important
in the context of typical delays that occur between the on-
set of AD symptoms and obtaining an AD diagnosis [6,7].
The results of this study should be interpreted in the
context of its limitations. First, while electronic medical
records data are extremely valuable for efficient and effect-
ive examination of health care resource utilisation, there
exist inherent limitations. Data are collected from routine
practice; thus, some data may be missing and coding er-
rors might have occurred. Second, the study analysed
the CPRD database of electronic medical records for GP
providers. Resource utilisation that occurred at the spe-
cialist level may not have been captured in the system, as
the database does not link patient records to all specialist
secondary care information (except HES). The lack ofcomplete secondary care information limited our ability to
draw conclusions about the role of the AD diagnostic
pathway (versus disease progression) in resource utilisa-
tion. Future studies should include evaluation of resource
utilisation at the specialist level. Third, we were also lim-
ited by the study design; inclusion in the study required a
documented AD diagnosis, so patients who did not visit a
physician or did not receive a diagnosis were not included
in the study population. Lastly, this study matched the AD
cohort with a general elderly control population by demo-
graphics and comorbidity index and adjusted for potential
available confounders, but an unmeasured confounder
may exist.
This study clearly shows that in the UK, AD imposes a
burden on the primary care system, particularly around
the time of diagnosis. Given the important role of GPs in
the lives of their patients, this finding is not surprising,
and is unlikely to change in the future. Because of their
long-term relationships with patients, GPs are uniquely
placed to observe cognitive changes in their patients over
time. However, it is important to recognise the additional
stress that this places on the primary care system.
Conclusions
Our study is the first to analyse the longitudinal pattern of
medical resource utilisation among patients with AD in
the UK. It shows a clear increase in primary care consulta-
tions, especially in the 6 months prior to AD diagnosis
and in the year post diagnosis, suggesting AD imposes a
substantial resource burden on UK primary care. Add-
itional research is necessary to estimate costs specifically
attributable to the diagnostic pathway. Economic evalua-
tions that address components of diagnostic procedures,
including those taking place at the specialist level, would
be valuable additions to the existing body of research on
resource utilisation patterns in patients with AD. This
would provide evidence to health plan sponsors who
want to facilitate mobilisation of appropriate AD-related
health care resources in a more time- and cost-effective
manner. Ultimately, this would ensure the efficient
provision of resources for AD diagnosis and treatment
and potentially alleviate the burden on primary care.
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